Moving forward with development of GSK1265744 (cabotegravir) for long-acting injectable PrEP in men and women

In this webinar, Raphael Landovitz, Protocol Chair, presented on HPTN 077—a Phase IIa safety, tolerability and acceptability study of an investigational injectable HIV integrase inhibitor, GSK1265744, for PrEP in HIV uninfected men and women. It is currently enrolling HIV uninfected men and women at low to minimal risk for acquiring HIV infection, ages 18 to 65.